Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles
By LabMedica International staff writers Posted on 18 Jan 2021 |

Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals aged over 75 years.
The neuropathological manifestations of AD traditionally include the accumulation of amyloid-beta (Aβ) peptide as extracellular plaques and hyperphosphorylated tau as intracellular neurofibrillary tangles (NFTs), typically identified on postmortem biopsy and used for definitive AD diagnosis.
A large team of scientists led by those at Icahn School of Medicine (New York, NY, USA) used transcriptome sequence data from more than 1,500 postmortem brain samples from individuals with or without AD to highlight several expression-based AD subtypes. They analyzed transcriptome data for more than 900 samples from the frontal pole (FP), superior temporal gyrus (STG), parahippocampal gyrus (PHG), and inferior frontal gyrus (IFG) brain regions in 364 Mount Sinai/JJ Peters VA Medical Center Brain Bank (MSBB-AD) participants with or without AD or related dementia.
The scientists focused in on differential gene expression patterns in the PHG, adjusting for AD stage and severity. Their results pointed to five PHG expression-based subtypes of AD, falling into three main clusters, along with related molecular signatures, clinical features, and potential driver genes. The team identified three major molecular subtypes of AD corresponding to different combinations of multiple dysregulated pathways, such as susceptibility to tau-mediated neurodegeneration, amyloid-β neuroinflammation, synaptic signaling, immune activity, mitochondria organization, and myelination. Multiscale network analysis reveals subtype-specific drivers such as GABRB2, LRP10, MSN, PLP1, and ATP6V1A. The team reported their results were shored up with data for postmortem brain samples from another 615 AD cases or controls in Religious Orders Study–Memory and Aging Project (ROSMAP).
Bin Zhang, PhD, a Professor of Genetics and genomic Science and senior author of the study, said, “Understanding the genetic and molecular differences between molecular subtypes of AD within these data will provide novel insights into disease pathogenesis and offer new avenues for developing effective therapeutics.” The study was published on January 6, 2021 in the journal Science Advances.
Related Links:
Icahn School of Medicine
The neuropathological manifestations of AD traditionally include the accumulation of amyloid-beta (Aβ) peptide as extracellular plaques and hyperphosphorylated tau as intracellular neurofibrillary tangles (NFTs), typically identified on postmortem biopsy and used for definitive AD diagnosis.
A large team of scientists led by those at Icahn School of Medicine (New York, NY, USA) used transcriptome sequence data from more than 1,500 postmortem brain samples from individuals with or without AD to highlight several expression-based AD subtypes. They analyzed transcriptome data for more than 900 samples from the frontal pole (FP), superior temporal gyrus (STG), parahippocampal gyrus (PHG), and inferior frontal gyrus (IFG) brain regions in 364 Mount Sinai/JJ Peters VA Medical Center Brain Bank (MSBB-AD) participants with or without AD or related dementia.
The scientists focused in on differential gene expression patterns in the PHG, adjusting for AD stage and severity. Their results pointed to five PHG expression-based subtypes of AD, falling into three main clusters, along with related molecular signatures, clinical features, and potential driver genes. The team identified three major molecular subtypes of AD corresponding to different combinations of multiple dysregulated pathways, such as susceptibility to tau-mediated neurodegeneration, amyloid-β neuroinflammation, synaptic signaling, immune activity, mitochondria organization, and myelination. Multiscale network analysis reveals subtype-specific drivers such as GABRB2, LRP10, MSN, PLP1, and ATP6V1A. The team reported their results were shored up with data for postmortem brain samples from another 615 AD cases or controls in Religious Orders Study–Memory and Aging Project (ROSMAP).
Bin Zhang, PhD, a Professor of Genetics and genomic Science and senior author of the study, said, “Understanding the genetic and molecular differences between molecular subtypes of AD within these data will provide novel insights into disease pathogenesis and offer new avenues for developing effective therapeutics.” The study was published on January 6, 2021 in the journal Science Advances.
Related Links:
Icahn School of Medicine
Latest Molecular Diagnostics News
- Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections
- Non-Biopsy Approach to Transform Adult Celiac Disease Diagnoses
- Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD
- First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
- New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
- Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
- Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
- Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
- Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
- Urine Test Diagnoses Early-Stage Prostate Cancer
- New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
- Spinal Fluid Biomarker for Parkinson’s Disease Offers Early and Accurate Diagnosis
- Revolutionary Blood Test Detects 30 Different Types of Cancers with 98% Accuracy
- Simple Blood Test Better Predicts Heart Disease Risk
- New Blood Test Detects 12 Common Cancers Before Symptoms Appear
- Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more